XML 33 R23.htm IDEA: XBRL DOCUMENT v3.19.2

Revenues (Tables)

6 Months Ended

Jun. 30, 2019

Revenue from Contract with Customer [Abstract]

Disaggregation of revenue by product and by geographic area

Revenues were as follows (in millions):

		Three months ended June 30,
		2019												2018
		US				ROW				Total				US				ROW				Total
Enbrel® (etanercept)		$	1,315			$	48			$	1,363			$	1,252			$	50			$	1,302
Neulasta® (pegfilgrastim)		719				105				824				948				152				1,100
Prolia® (denosumab)		458				240				698				396				214				610
XGEVA® (denosumab)		379				120				499				339				113				452
Aranesp® (darbepoetin alfa)		192				244				436				241				231				472
KYPROLIS® (carfilzomib)		166				101				267				151				112				263
EPOGEN® (epoetin alfa)		223				—				223				250				—				250
Sensipar®/Mimpara® (cinacalcet)		43				79				122				330				90				420
Other products		647				495				1,142				460				350				810
Total product sales(1)		$	4,142			$	1,432			5,574				$	4,367			$	1,312			5,679
Other revenues										297												380
Total revenues										$	5,871											$	6,059

		Six months ended June 30,
		2019												2018
		US				ROW				Total				US				ROW				Total
ENBREL		$	2,421			$	93			$	2,514			$	2,302			$	105			$	2,407
Neulasta®		1,612				233				1,845				1,957				298				2,255
Prolia®		848				442				1,290				716				388				1,104
XGEVA®		735				235				970				671				226				897
Aranesp®		374				476				850				466				460				926
KYPROLIS®		320				192				512				288				197				485
EPOGEN®		442				—				442				494				—				494
Sensipar®/Mimpara®		178				157				335				739				178				917
Other products		1,203				899				2,102				881				656				1,537
Total product sales(1)		$	8,133			$	2,727			10,860				$	8,514			$	2,508			11,022
Other revenues										568												591
Total revenues										$	11,428											$	11,613

^____________ 

⁽¹⁾ 

Hedging gains and losses, which are included in product sales, were not material for the three and six months ended June 30, 2019 and 2018.

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration